



January 14, 2020

Company name: Mitsubishi Tanabe Pharma Corporation
Representative: Masayuki Mitsuka
President & Representative Director
Code number: 4508, First Section, Tokyo Stock Exchange
Contact: Yoshiaki Takai, Vice President,
Head of Corporate Communications Dept.
(TEL: +81-6-6205-5211)

Change in Representative Director

Osaka (January 14, 2020) – The Board of Directors of Mitsubishi Tanabe Pharma Corporation has today approved the following proposal to appoint a new Representative Director.

1. Change in Representative Director (effective April 1, 2020)

New Role	Name	Current Role
Member of the Board	Masayuki Mitsuka	President Representative Director
President Representative Director	Hiroaki Ueno	Member of the Board, Managing Executive Officer, in charge of Human Resources Department, Legal & General Affairs Department, International Business Department, China Operations Management Office, ASEAN Business, Europe Operations Management Office, Public Affairs & Policy Department

2. Reason for the Change

In order to respond to rapid changes in the business environment, it is important to accelerate global business expansion, acquire the latest technologies, and secure new business opportunities. As Mitsubishi Tanabe Pharma will be formulating its next mid-term management plan and moving to a new phase in fiscal 2020, the company decided to transition to the next generation of management.

Under the new leadership structure, the company will strive to strengthen its management and enhance its corporate value toward further progress.

3. Biography of the New Representative Director

Name: Hiroaki Ueno, Ph.D.
Date of birth: September 8, 1958 (61 years old)
Education: Completed a master's course at the Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology
Number of company shares owned: 4,920

Professional Career:

April 1983	Entered Mitsubishi Chemical Industries Ltd.
July 2005	General Manager of Medicinal Research Laboratories IV of Research Department of Sohyaku Division of Mitsubishi Pharma Corporation
July 2006	General Manager of Chemistry Research Laboratories of Sohyaku and Research Division of Mitsubishi Pharma Corporation
October 2007	General Manager of Chemistry Department II of Medicinal Chemistry Research Laboratories of Research Division of the Company
April 2010	General Manager of Medicinal Chemistry Research Laboratories II of Research Division of the Company
April 2012	General Manager of Medicinal Chemistry Research Laboratories II of Research Division of the Company
April 2014	Executive Officer, General Manager of Research Strategy & Planning Department of Research Division of the Company
April 2015	Executive Officer, Division Manager of CMC Division (Chemistry, Manufacturing and Control) of the Company
April 2017	Executive Officer, Division Manager of Sohyaku. Innovative Research Division of the Company
April 2018	Managing Executive Officer, Division Manager of Sohyaku. Innovative Research Division, in charge of Intellectual Property and Contract Department of the Company
April 2019	Managing Executive Officer, in charge of Human Resources Department, General Affairs Department, International Business Department, China Operations Management Office, ASEAN Business, Europe Operations Management Office, Public Affairs & Policy Department of the Company
June 2019	Member of the Board, Managing Executive Officer, in charge of Human Resources Department, General Affairs Department, International Business Department, China Operations Management Office, ASEAN Business, Europe Operations Management Office, Public Affairs & Policy Department of the Company
October 2019	Member of the Board, Managing Executive Officer, in charge of Human Resources Department, Legal & General Affairs Department,

April 2020 International Business Department, China Operations Management Office, ASEAN Business, Europe Operations Management Office, Public Affairs & Policy Department of the Company (Current)
To be appointed President and Representative Director of the Company

4. Planned Date of Change

April 1, 2020

-End-